Company Overview and Strategy - Mobile Infrastructure owns a diversified portfolio of parking assets primarily in the Midwest and Southwest, with new management since 2021[6] - The company aims to improve revenue consistency and NOI margin by converting from leased to managed contracts, leveraging data analytics[6] - Mobile Infrastructure intends to become a preferred acquirer in the parking industry through tax-efficient acquisitions and a track record of increasing revenue and profitability of acquired assets[6] - The company has a potential acquisition pipeline of $300 million, which can be pursued as financial market conditions improve[6, 41] Financial Performance and Metrics - The company's NAV is $7.25 per share, with assets having a significantly higher replacement cost[6] - Total portfolio includes 40 parking facilities, with 22 lots and 18 garages, across 20 markets, encompassing approximately 15,100 parking spaces[10] - Top ten assets account for 55.9% of total spaces and 65.4% of revenue[14] - Same Location RevPAS increased from $170.09 in 1Q22 to $200.44 in 4Q24[20] - Total revenues increased by 16.0% from $7.892 million in 4Q23 to $9.157 million in 4Q24[45] - Net Operating Income increased by 7.2% from $21.109 million YTD 2023 to $22.633 million YTD 2024[45] Market and Industry Position - The U S parking industry generates approximately $131 billion in annual revenue, representing about 1% of the U S GDP[30]

Financial Highlights - Q4 2024 revenue reached RMB 19407 million, a 4% year-over-year increase[13, 51] - FY24 revenue totaled RMB 56 billion, up 18% year-over-year[13] - Q4 2024 gross profit was RMB 411 million, with a gross margin of 21%[13, 53] - FY24 gross profit amounted to RMB 1154 million, with a gross margin of 21%[13] - Q4 2024 adjusted EBITDA was RMB 744 million, resulting in an adjusted EBITDA margin of 4%[55, 70] - Q4 2024 net loss was RMB 395 million, representing a net margin of -2%[57, 67] - FY24 net loss was RMB 9899 million[67] Operational Metrics - ECARX products are integrated into over 81 million vehicles as of December 31, 2024[13] - The company serves 18 OEMs across 28 vehicle brands as of December 31, 2024[13] - Geely Geome E02 achieved cumulative shipments of over 21 million as of December 31, 2024[38] Product and Technology - ECARX has a major presence across three continents with R&D centers and operation centers[17, 18, 21, 22] - ECARX Cloudpeak software solution offers customizable cross-domain software development solutions[27] - ECARX is developing AI solutions including AI Voice, AI Scene Engine, and ADAS Copilot[31]

Core Insights - The company reported a fourth quarter revenue growth of 41.8%, reaching $31.1 million, driven by strong performance across all segments, particularly in Safety Tech and Aeronautics [1][8] - The adjusted net loss for the quarter narrowed to $3.7 million from $11.2 million in the prior year, marking a significant improvement in profitability [1][11] - The company achieved its first-ever quarter of positive adjusted EBITDA at $0.2 million, compared to a negative $6.0 million in the same quarter last year [1][11] - Full-year sales surpassed $100 million for the first time, with over 80% of sales coming from recurring customers [1][5] - The company introduced a 10-year committed and contracted backlog, indicating strong long-term demand across segments [1] - Initial guidance for 2025 anticipates healthy double-digit revenue growth and the first full year of positive adjusted EBITDA [1][19] Fourth Quarter 2024 Highlights - Revenue for the fourth quarter increased to $31.1 million, a 41.8% increase from $22.0 million in Q4 2023 [7][8] - Gross profit for the quarter was $11.4 million, up 81.4% from $6.3 million in the prior year, with a gross margin improvement to 36.5% from 28.5% [9][10] - Total operating expenses rose to $15.8 million, a 5.5% increase compared to $15.0 million in Q4 2023, primarily due to increased stock-based compensation [10] Full Year 2024 Highlights - Total revenue for the full year reached $103.5 million, a 32.8% increase from $78.0 million in 2023 [7] - The gross margin for the full year improved to 28.7%, up 310 basis points from 25.6% in the previous year [7] - The net loss for the year was $53.2 million, reduced from a loss of $79.3 million in 2023 [7] Segment Performance - **Safety-Tech Division**: Revenue increased by 73.0% to $13.0 million, with gross profit rising 212.7% to $3.0 million [12] - **Aeronautics Division**: Revenue grew by 26.7% to $13.4 million, with gross profit increasing 62.2% to $6.8 million [13] - **Architecture Division**: Revenue rose by 31.8% to $4.1 million, with gross profit up 54.8% to $1.5 million [16] - **Automotive Division**: Revenue decreased by 14.7% to $0.7 million, reflecting timing impacts of full-year orders [17] Financial Position - As of December 31, 2024, the company had total liquidity of $40.6 million, including $5.6 million in cash and a $35.0 million undrawn credit facility [18] - Total debt stood at $38.4 million, with a significant portion being short-term receivable financings [18] Future Outlook - The company expects full-year revenue for 2025 to be in the range of $130 million to $140 million, representing approximately 30% growth compared to 2024 [19] - The anticipated positive adjusted EBITDA for 2025 is expected to be supported by a strong recurring revenue base and operational leverage [19]

Financial Data and Key Metrics Changes - Consolidated revenue for Q4 2024 decreased by 1.9% to $102.9 million, while full-year revenue for 2024 decreased by 0.8% to $425.2 million [22][30] - Consolidated gross profit for Q4 2024 was $33.5 million, slightly down from $33.6 million in the previous year, with a gross margin increase of 40 basis points to 32.5% [24] - Consolidated adjusted EBITDA for Q4 2024 decreased by 2.8% to $11.1 million, while full-year adjusted EBITDA was at the upper end of guidance at $48.5 million, down from $58.2 million in 2023 [27][32] - Consolidated net loss attributable to common shareholders decreased to $15.3 million or $0.58 per share from $24.5 million or $0.90 per share a year earlier [29] Business Line Data and Key Metrics Changes - GRE (Retail Energy) revenue remained unchanged at $98.4 million, with electricity revenue also flat at $82.1 million, contributing 83.5% of GRE's revenues [22][30] - GREW (Renewables) revenue for Q4 2024 decreased by 30.1% to $4.5 million, while full-year revenue increased by 16.1% to $21.9 million [23][31] - Diversegy, part of GREW, recorded a 70% revenue increase and a gross profit increase of 130%, generating over $750,000 in income from operations [13] Market Data and Key Metrics Changes - The company added 23,000 net new meters in Q4 2024 and over 60,000 for the full year, marking a nearly 17% increase [6] - Revenue from natural gas sales increased by 7.5% in Q4 2024 to $16.2 million, reflecting growth in both gas meter base and revenue per Therm sold [22] Company Strategy and Development Direction - The company plans to continue building its meter book in 2025, with a focus on the Texas dynamic electricity market and natural gas in California [8] - Genie Solar has completed its strategic migration to utility-scale project verticals, aiming to capture long-term residual value from power generated [14] - The company intends to use asset-backed finance deals to monetize operational raises and boost returns on equity [15] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in achieving strong adjusted EBITDA and profitability in 2025, with expectations to continue cash reserve growth and stock buybacks [18] - The management highlighted the operational and financial performance in 2024 as consistent with expectations, setting the stage for better performance in 2025 [21][38] Other Important Information - The company repurchased approximately 168,000 shares in Q4 2024 for $2.5 million and a total of 661,000 shares for $10.4 million throughout the year [37] - Cash and cash equivalents totaled $201 million at the end of 2024, an increase of $37.6 million over the year [36] Q&A Session Summary Question: No questions were raised during the Q&A session - The conference call concluded without any questions from participants [39]

Core Insights - Advantage Solutions Inc. reported a significant decline in revenues and an increase in net loss for the year ended December 31, 2024, while achieving growth in Adjusted EBITDA [2][4][5] - The company is focused on transformation initiatives aimed at enhancing operational efficiencies and capabilities, with expectations for revenue and Adjusted EBITDA growth in 2025 [1][4] Financial Performance - For Q4 2024, total revenues were $892.3 million, a decrease of 10.0% from $991.9 million in Q4 2023, with a net loss of $177.9 million compared to a net loss of $2.7 million [2][3] - For the full year 2024, total revenues were $3,566.3 million, down 8.6% from $3,900.1 million in 2023, with a net loss of $378.4 million compared to a net loss of $81.2 million [2][3] - Adjusted EBITDA for Q4 2024 increased by 8.9% to $94.6 million, and for the full year, it rose by 1.1% to $356.0 million [5][3] Operational Highlights - The company achieved healthy profit performance in 2024 across its Experiential Services and Retailer Services segments while adjusting its Branded Services to align with market demand [5] - Advantage Solutions executed disciplined capital allocation strategies, including voluntary debt repurchases and share buybacks totaling approximately $158 million and $34 million, respectively [5] Future Outlook - Management anticipates growth in revenues and Adjusted EBITDA in 2025, indicating a positive outlook for the company's operational strategies and market positioning [1][4]

Financial Highlights - Full Year 2024 Revenue reached $624.6 million, a 4% year-over-year increase[9] - Full Year 2024 Adjusted EBITDA was $72.3 million, a 21% year-over-year increase[11,12] - Cash as of December 31, 2024, was $158.9 million, a 10% year-over-year increase[12] - Fourth Quarter 2024 Adjusted EBITDA was $31.4 million, exceeding guidance[13] - Full Year 2024 Net income available to common shareholders was $10.1 million[9,53] Enrollment Trends - APUS delivered 3% year-over-year enrollment growth with an EBITDA margin of 30% on $317 million in revenue[12] - APUS 4Q24 registration growth was 7% compared to 4Q23[13,48] - Rasmussen experienced year-over-year enrollment growth starting in 3Q24 and achieved positive EBITDA in 2H24[12,49] - Hondros enrollments have grown year-over-year for the last 20 consecutive quarters[24,33] 2025 Outlook - The company projects 2025 revenue between $650 million and $660 million[16] - The company projects 2025 Adjusted EBITDA between $75 million and $85 million[16] - The company projects 2025 Net income available to common shareholders between $19 million and $26 million[16] Strategic Initiatives - APEI plans to combine APUS, Rasmussen, and Hondros College of Nursing into American Public University System by year-end 2025[17,19]

Financial Data and Key Metrics Changes - Total revenue for 2024 was over $203 million, growing 24% year-over-year, driven by strong demand for Recorlev and Gvoke [8][14] - Net product revenue for Q4 2024 was $57 million, marking a 34% increase compared to the prior year [28] - Adjusted EBITDA turned positive in Q4 2024, with expectations to remain positive going forward [15][43] Business Line Data and Key Metrics Changes - Recorlev achieved $64.3 million in revenue for 2024, a 118% increase compared to 2023, with Q4 revenue of $22.6 million, up 131% year-over-year [9][28] - Gvoke generated nearly $83 million in revenue for 2024, a 24% increase, with Q4 revenue of $23.3 million, also a 25% increase [10][30] - Keveyis ended 2024 with approximately $50 million in revenue, a 13% decline year-over-year, but maintained a steady patient base [11][36] Market Data and Key Metrics Changes - The market for hypercortisolemia is expanding, with increasing diagnoses leading to more patients being treated [16][17] - Gvoke targets a large untapped market, with an estimated 14 million patients unprotected by life-saving therapies [18][19] Company Strategy and Development Direction - The company aims for total revenue between $255 million and $275 million in 2025, representing over 30% year-over-year growth at the midpoint [14][36] - Strategic priorities include driving growth of commercial products, maintaining financial discipline, and enhancing communication with stakeholders [13] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in continued growth, particularly for Recorlev and Gvoke, while anticipating steady demand for Keveyis [36][38] - The company is focused on leveraging its existing commercial capabilities for the development of XP-8121, a new product for hypothyroidism [25][102] Other Important Information - The company reported a gross margin of 84% in Q4 2024, a 1% improvement year-over-year, driven by a favorable product mix [32] - The company ended 2024 with a healthy cash position of $71.6 million [35] Q&A Session Summary Question: Recorlev strength and prescriber growth - Management noted both expansion of the writer base and increased prescriptions from existing prescribers contributing to Recorlev's growth [47] Question: Year-over-year prescription growth in hypercortisolism - Management indicated a lack of specific data on market growth but emphasized the importance of field efforts to identify patients [49] Question: Expectations for Keveyis in 2025 - Management suggested Keveyis may have found its bottom, with expectations to hold steady despite potential pressures on reimbursement [54] Question: Long-term spend to support Recorlev - Management acknowledged the need for continued investment in Recorlev, with a focus on expanding awareness and treatment [81][88] Question: Durability and exclusivity runway for Recorlev - Patents for Recorlev extend to 2040, with orphan exclusivity through 2028, providing a significant runway for growth [84][86] Question: Gvoke and updated guidelines - Management is focused on raising awareness of new guidelines to protect unprotected patients, viewing it as a long-term opportunity [94] Question: Phase 3 readiness for XP-8121 - Management confirmed plans for Phase 3 readiness, with potential clinical trials starting in 2026 [95]

Financial Performance - The company's consolidated adjusted EBITDA for 2024 was $78.9 million, with an adjusted EBITDA margin of 13.8%[5,6,8] - Full year 2024 revenue was $571.1 million[5,8] - Free cash flow for 2024 was $50.4 million[8,12] - Q4 2024 revenue was $143.1 million, with an adjusted EBITDA of $21.9 million and an adjusted EBITDA margin of 15.3%[14,16] - Q4 2024 free cash flow was $27.3 million[12,16] Segment Highlights - High Specification Rigs business experienced 7% year-over-year growth in core business[9] - High-Specification Rigs segment Q4 2024 Adjusted EBITDA increased 23% over the prior year's quarter[21] - Processing Solutions & Ancillary Services segment achieved a full year 2024 Adjusted EBITDA margin of 21.3%[27] - Wireline Services segment realized 11% year-over-year revenue growth in Production Wireline[32] Shareholder Returns - The company announced a 20% increase to the base dividend[12] - $20 million, representing 40% of the $50.4 million in 2024 Free Cash Flow, was returned to shareholders[12] - The company repurchased 1,520,000 shares during 2024 for $15.5 million at an average price of $10.11 per share[12]

Financial Data and Key Metrics Changes - The company reported a 7% increase in net revenue for Q4 2024, totaling $33.8 million, compared to the prior year [18] - Gross margins increased by 2% year-over-year to 52.2% [8] - Operating income rose by 69% to $6.9 million, while adjusted EBITDA increased by 13% to $25.3 million, with an adjusted EBITDA margin of 18.8% for the full year [9][10] Business Line Data and Key Metrics Changes - Revenue growth was observed across almost all business lines, with oncology and pain management increasing by 6.1% and 14.7% respectively [11] - Equipment rentals in device solutions grew by 13.6%, and equipment sales increased by 20.6% due to a significant transaction in Q3 [11] - Advanced wound care revenue surged by 342%, while the wound care segment overall was below expectations due to a strategic pause in onboarding new initiatives [12][19] Market Data and Key Metrics Changes - The company noted a strong demand for advanced wound care products and biomed services, indicating a ripe opportunity for growth in these areas [41] - The addressable market for Chemo Mouthpiece is estimated to be around $500 to $600 million, highlighting significant potential for revenue generation [67] Company Strategy and Development Direction - The company aims for revenue growth of 8% to 10% in 2025, with adjusted EBITDA margins expected to exceed 18.8% [34] - Focus on less capital-intensive revenue sources, such as biomedical services and advanced wound care supplies, is expected to drive future growth [26][34] - The company is strategically pausing some wound care initiatives to ensure quality and alignment with existing resources before ramping up in 2025 [12] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in achieving growth across all business lines in 2025, particularly in advanced wound care and biomed [43] - The sales cycle for Chemo Mouthpiece is anticipated to gain momentum in the coming months, with clinical studies expected to enhance market adoption [49][70] - The company expects to see benefits from improvements in the referral process throughout 2025, with gradual enhancements in operational efficiency [55] Other Important Information - The effective tax rate for Q4 2024 was reported at 59%, primarily due to equity compensation deductions and other non-cash tax expenses [22][23] - The company’s net debt decreased to $23.3 million, with strong liquidity reserves of over $51 million as of December 31, 2024 [27][28] Q&A Session Summary Question: Growth expectations for Advanced Wound Care products - Management indicated that Advanced Wound Care is expected to drive most of the growth in 2025, with significant opportunities from DME partners [41][43] Question: Feedback on Chemo Mouthpiece from oncology centers - Management noted growing interest and small orders for Chemo Mouthpiece, with expectations for broader adoption following the publication of clinical studies [46][49] Question: Improvements in the referral process - Management explained that improvements in the referral process will ramp throughout the year, with some benefits expected in Q1 [53][55] Question: Addressable market for Chemo Mouthpiece and Dignitana - Management stated that Chemo Mouthpiece has a large addressable market, while Dignitana represents a smaller but significant opportunity [66][67] Question: Factors contributing to EBITDA margin improvement - Management highlighted continued efficiencies in biomed and growth in other areas as key contributors to improved EBITDA margins [72][75]

Core Viewpoint - American Public Education, Inc. (APEI) is expected to report its fourth-quarter 2024 results on March 6, with a focus on revenue growth and enrollment trends across its segments [1]. Financial Performance - In the last reported quarter, APEI's earnings per share (EPS) exceeded the Zacks Consensus Estimate by 300%, while revenues fell short by 0.3%. Year-over-year, revenues increased by 1.5% and EPS rose by 100% [2]. - The Zacks Consensus Estimate for the fourth-quarter EPS is stable at 54 cents, indicating a 15.6% decrease from the previous year's EPS of 64 cents. Revenue estimates are pegged at $161.6 million, suggesting a 5.7% year-over-year rise [3]. Enrollment and Revenue Growth - APEI's fourth-quarter revenues are anticipated to increase due to strong performance across all segments, particularly in the American Public University System (APUS) and Hondros College of Nursing (HCN) [4]. - APUS is expected to see total net course registrations grow by 4% to 6%, driven by military-affiliated programs. HCN's enrollment is projected to rise by 19% to 3,700 students, while Rasmussen University (RU) is expected to have a 4% increase in student enrollment to 14,600 [6]. Segment Revenue Expectations - For the fourth quarter, revenues in the APUS and HCN segments are expected to increase by 2.8% to $81.6 million and by 20.6% to $19 million, respectively. RU segment revenues are predicted to grow by 5.4% to $55.4 million [7]. Margin and Income Projections - APEI is expected to report net income between $9 million and $11 million, down from $11.5 million a year ago, translating to EPS between 47 cents and 56 cents [9]. - Adjusted EBITDA is projected to be between $23 million and $26 million, compared to $25.7 million a year ago, with adjusted EBITDA margins expected to decline by 70 basis points to 16.1% [9]. Earnings Prediction Model - The current model does not predict a definitive earnings beat for APEI, as the Earnings ESP stands at 0.00% and the company holds a Zacks Rank of 3 (Hold) [10][11].